FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914486061> ?p ?o ?g. }

• W2914486061 endingPage "608" @default.
• W2914486061 startingPage "599" @default.
• W2914486061 abstract "Checkpoint inhibitors have recently been approved for the treatment of patients with hepatocellular carcinoma (HCC). However, biomarkers, which will help identify patients responding to therapy, are missing. We recently tested the combination of anti-CTLA4 treatment (tremelimumab) with loco-regional therapy in patients with HCC and reported a partial response rate of 26%.Here, we report updated survival analyses and results from our immune monitoring studies on peripheral blood mononuclear cells (PBMCs) and tumors from these patients.Tremelimumab therapy increased CD4+-HLA-DR+, CD4+PD-1+, CD8+HLA-DR+, CD8+PD-1+, CD4+ICOS+ and CD8+ICOS+ T cells in the peripheral blood of the treated patients. Patients with higher CD4+PD1+ cell frequency at baseline were more likely to respond to tremelimumab therapy. PD-1 expression was increased on alpha fetal protein (AFP) and survivin-specific CD8 T cells upon tremelimumab treatment. An increase of tumor infiltrating CD3+ T cells were also seen in these patients. Immunosequencing of longitudinal PBMC showed that one cycle of tremelimumab significantly decreased peripheral clonality, while no additional effects were seen after loco-regional therapy.In summary, we observed a clear activation of T cell responses in HCC patients treated with tremelimumab and identified potential biomarkers which will help identify patients responding to immunotherapy with anti-CTLA4." @default.
• W2914486061 created "2019-02-21" @default.
• W2914486061 creator A5002278734 @default.
• W2914486061 creator A5019378601 @default.
• W2914486061 creator A5024024043 @default.
• W2914486061 creator A5025086832 @default.
• W2914486061 creator A5025349228 @default.
• W2914486061 creator A5033604808 @default.
• W2914486061 creator A5043286130 @default.
• W2914486061 creator A5043319996 @default.
• W2914486061 creator A5057000867 @default.
• W2914486061 creator A5058601536 @default.
• W2914486061 creator A5064127666 @default.
• W2914486061 creator A5068012456 @default.
• W2914486061 creator A5079418869 @default.
• W2914486061 creator A5080146061 @default.
• W2914486061 creator A5086069417 @default.
• W2914486061 creator A5089581942 @default.
• W2914486061 date "2019-01-28" @default.
• W2914486061 modified "2023-10-14" @default.
• W2914486061 title "The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma" @default.
• W2914486061 cites W1965827638 @default.
• W2914486061 cites W1990381878 @default.
• W2914486061 cites W1998518732 @default.
• W2914486061 cites W1998927848 @default.
• W2914486061 cites W2039123767 @default.
• W2914486061 cites W2043071551 @default.
• W2914486061 cites W2102862705 @default.
• W2914486061 cites W2124130126 @default.
• W2914486061 cites W2338576144 @default.
• W2914486061 cites W2345150791 @default.
• W2914486061 cites W2546700240 @default.
• W2914486061 cites W2568328220 @default.
• W2914486061 cites W2586907906 @default.
• W2914486061 cites W2606151758 @default.
• W2914486061 cites W2606367731 @default.
• W2914486061 cites W2619463261 @default.
• W2914486061 cites W2626033245 @default.
• W2914486061 cites W2754580992 @default.
• W2914486061 cites W2796227807 @default.
• W2914486061 cites W2805592007 @default.
• W2914486061 doi "https://doi.org/10.1007/s00262-019-02299-8" @default.
• W2914486061 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6662600" @default.
• W2914486061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30688989" @default.
• W2914486061 hasPublicationYear "2019" @default.
• W2914486061 type Work @default.
• W2914486061 sameAs 2914486061 @default.
• W2914486061 citedByCount "80" @default.
• W2914486061 countsByYear W29144860612019 @default.
• W2914486061 countsByYear W29144860612020 @default.
• W2914486061 countsByYear W29144860612021 @default.
• W2914486061 countsByYear W29144860612022 @default.
• W2914486061 countsByYear W29144860612023 @default.
• W2914486061 crossrefType "journal-article" @default.
• W2914486061 hasAuthorship W2914486061A5002278734 @default.
• W2914486061 hasAuthorship W2914486061A5019378601 @default.
• W2914486061 hasAuthorship W2914486061A5024024043 @default.
• W2914486061 hasAuthorship W2914486061A5025086832 @default.
• W2914486061 hasAuthorship W2914486061A5025349228 @default.
• W2914486061 hasAuthorship W2914486061A5033604808 @default.
• W2914486061 hasAuthorship W2914486061A5043286130 @default.
• W2914486061 hasAuthorship W2914486061A5043319996 @default.
• W2914486061 hasAuthorship W2914486061A5057000867 @default.
• W2914486061 hasAuthorship W2914486061A5058601536 @default.
• W2914486061 hasAuthorship W2914486061A5064127666 @default.
• W2914486061 hasAuthorship W2914486061A5068012456 @default.
• W2914486061 hasAuthorship W2914486061A5079418869 @default.
• W2914486061 hasAuthorship W2914486061A5080146061 @default.
• W2914486061 hasAuthorship W2914486061A5086069417 @default.
• W2914486061 hasAuthorship W2914486061A5089581942 @default.
• W2914486061 hasBestOaLocation W29144860612 @default.
• W2914486061 hasConcept C126322002 @default.
• W2914486061 hasConcept C137061746 @default.
• W2914486061 hasConcept C143998085 @default.
• W2914486061 hasConcept C167672396 @default.
• W2914486061 hasConcept C202751555 @default.
• W2914486061 hasConcept C203014093 @default.
• W2914486061 hasConcept C2776090121 @default.
• W2914486061 hasConcept C2777701055 @default.
• W2914486061 hasConcept C2778019345 @default.
• W2914486061 hasConcept C2778650287 @default.
• W2914486061 hasConcept C2781433595 @default.
• W2914486061 hasConcept C55493867 @default.
• W2914486061 hasConcept C71924100 @default.
• W2914486061 hasConcept C86803240 @default.
• W2914486061 hasConcept C8891405 @default.
• W2914486061 hasConcept C90924648 @default.
• W2914486061 hasConceptScore W2914486061C126322002 @default.
• W2914486061 hasConceptScore W2914486061C137061746 @default.
• W2914486061 hasConceptScore W2914486061C143998085 @default.
• W2914486061 hasConceptScore W2914486061C167672396 @default.
• W2914486061 hasConceptScore W2914486061C202751555 @default.
• W2914486061 hasConceptScore W2914486061C203014093 @default.
• W2914486061 hasConceptScore W2914486061C2776090121 @default.
• W2914486061 hasConceptScore W2914486061C2777701055 @default.
• W2914486061 hasConceptScore W2914486061C2778019345 @default.
• W2914486061 hasConceptScore W2914486061C2778650287 @default.
• W2914486061 hasConceptScore W2914486061C2781433595 @default.

• next